Key Performance
More- Earnings Score: N/A
- Momentum Score: 29
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
INmune Bio announced statistically significant results from its Phase 2 MINDFuL trial of XPro1595 in early Alzheimer's disease patients. The drug showed a significant treatment effect on white matter myelin (p=0.0028) in the full study population (n=200) and strengthened further in inflammation-enriched patients (p=0.0098). The company has secured FDA Fast Track designation and End-of-Phase 2 alignment for an integrated Phase 2b/3 registrational program.
06/02/2026, 8:00 AM • GlobeNewswire
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
INmune Bio Inc. (NASDAQ: INMB) announced that Phase 2 MINDFuL trial results for XPro™ (XPro1595, pegipanermin) in mild Alzheimer's disease with inflammation have been published in NPJ Dementia. In a pre-specified enriched subgroup (n=100) with amyloid-beta positivity and inflammation biomarkers, XPro™ showed directionally consistent benefits across cognitive, functional, behavioral, and biomarker endpoints over 24 weeks with no serious adverse events. The company received FDA Fast Track designation for the program.
05/15/2026, 8:00 AM • GlobeNewswire
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
INmune Bio announced that the FDA has granted Fast Track designation to XPro (pegipanermin), a first-in-class selective soluble TNF inhibitor, for treating early Alzheimer's disease including mild cognitive impairment and mild dementia. The designation facilitates expedited development and review, recognizing the urgent need for treatments addressing neuroinflammation in Alzheimer's. The company plans to execute a Phase 2b/3 precision-medicine registrational program targeting patients with biomarkers of inflammation.
05/14/2026, 8:00 AM • GlobeNewswire
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
INmune Bio announced Q1 2026 financial results showing a net loss of $5.4 million, down from $9.7 million in Q1 2025. The company made progress on its CORDStrom™ platform with a planned UK MAA submission in mid-summer, advanced XPro™ to an adaptive Phase 2b/3 registrational pathway for early Alzheimer's Disease, and reported new preclinical data for INB03 in breast cancer. The company had $21.4 million in cash as of May 7, 2026.
05/07/2026, 4:00 PM • GlobeNewswire
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company focused on inflammation and immunology, announced it will host a conference call on May 7th, 2026 at 4:30 PM ET to discuss Q1 2026 financial results and provide a corporate update. The company is developing treatments targeting the innate immune system across three product platforms: CORDStrom, XPro, and INKmune.
04/30/2026, 8:00 AM • GlobeNewswire
INmune Bio's Phase 2 MINDFuL trial of XPro (pegipanermin) will be featured at the AD/PD 2026 conference as a successful example of biomarker enrichment strategy in Alzheimer's drug development. The trial showed consistent efficacy signals in inflamed patient subgroups, and the company has received FDA alignment to advance to a Phase 2b/3 registrational program for early Alzheimer's patients with inflammatory biomarkers.
03/19/2026, 8:00 AM • GlobeNewswire
A peer-reviewed study published in Cytotherapy explores the potential of mesenchymal stromal cell (MSC) therapies, focusing on systemic delivery, local delivery methods, and in vivo persistence of cell treatments.
12/05/2025, 7:00 AM • GlobeNewswire
INmune Bio Inc. will host a conference call on August 7th, 2025 at 4:30pm EDT to discuss Q2 2025 financial results and provide a corporate update, focusing on their clinical-stage inflammation and immunology research.
07/31/2025, 7:00 AM • GlobeNewswire
INmune Bio will host a conference call on June 30, 2025, to present top line data from their Phase 2 MINDFuL trial investigating XPro™ treatment for early Alzheimer's Disease, focusing on patients with mild cognitive impairment and neuroinflammation markers.
06/26/2025, 4:00 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/03/2026
Company Profile
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.